ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL-2 R alpha

IL-2 R alpha

概要

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,Insulin-Dependent Diabetes Mellitus 10,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,Interleukin-2 Receptor alpha Subunit,IL-2R alpha
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
ILA-C52H8 Cynomolgus Cynomolgus IL-2 R alpha / CD25 Protein, His Tag (MALS verified)
ILA-C52H8-structure
ILA-C52H8-sds
ILA-H82F9 Human Biotinylated Human IL-2 R alpha / CD25 Protein, Fc,Avitag™ (MALS verified)
ILA-H82F9-structure
ILA-H82F9-sds
ILA-C52H4 Canine Canine IL-2 R alpha / CD25 Protein, His Tag
ILA-C52H4-structure
ILA-C52H4-sds
ILA-M52H9 Mouse Mouse IL-2 R alpha / CD25 Protein, His Tag
ILA-M52H9-structure
ILA-M52H9-sds
ILA-H82E6 Human Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade
ILA-H82E6-structure
ILA-H82E6-sds
ILA-H52H9 Human Human IL-2 R alpha / CD25 Protein, His Tag
ILA-H52H9-structure
ILA-H52H9-sds
ILA-H5251 Human Human IL-2 R alpha / CD25 Protein, Fc Tag (MALS verified)
ILA-H5251-structure
ILA-H5251-sds
ACRO Quality

生物活性データの一部

ILA-H82E6-Cell-based assay
IL-2 R alpha CELL

Biotinylated Human IL-2 R alpha, His,Avitag, premium grade (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).

Protocol
ILA-H52H9-Cell-based assay
IL-2 R alpha CELL

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) inhibits the IL-2 dependent proliferation of Mo7e cells. The EC50 for this effect is 0.35-0.77 µg/mL (Routinely tested).

Protocol
ILA-H52H9-SPR
IL-2 R alpha SPR

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
ILA-H5251-SPR
IL-2 R alpha SPR

Human IL-2 R alpha Protein, Fc Tag (Cat. No. ILA-H5251) captured on CM5 chip via anti-human IgG Fc antibody can bind Human IL-2, Tag Free with an affinity constant of 10.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested)

Protocol

カスタマーレビュー

Synonym Name

IL2RA,CD25,p55,IL2-RA,IL-2-RA

Background

Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Clinical and Translational Updates

相関分子

IL-2

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daclizumab biosimilar (Shanghai CP Guojian) Approved Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Rejection of organ transplantation F. Hoffmann-La Roche Ag 1997-12-10 Arthritis, Juvenile; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Lymphoma; Iritis; Uveitis; Thrombocytopenia; Rejection in heart transplantation; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Retinal Diseases; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; HTLV-I Infections; Myelodysplastic Syndromes; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Leukemia; Granulomatosis with Polyangiitis; HIV Infections; Diabetes Mellitus, Type 1 Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect United States Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Kidney Diseases; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Rejection of organ transplantation F. Hoffmann-La Roche Ag 1997-12-10 Arthritis, Juvenile; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Lymphoma; Iritis; Uveitis; Thrombocytopenia; Rejection in heart transplantation; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Retinal Diseases; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; HTLV-I Infections; Myelodysplastic Syndromes; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Leukemia; Granulomatosis with Polyangiitis; HIV Infections; Diabetes Mellitus, Type 1 Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect United States Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Kidney Diseases; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Plc Graft vs Host Disease Details
Nemvaleukin alfa RDB-1419; RDB-1450; ALKS-4230 Phase 3 Clinical Alkermes Plc Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
PT-101 PT-101; MK-6194; PT101 Phase 2 Clinical Pandion Therapeutics Lupus Erythematosus, Systemic; Colitis, Ulcerative; Dermatitis, Atopic; Vitiligo Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Melanoma Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Adc Therapeutics Sa, Genmab A/S Myeloproliferative Disorders; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myelodysplastic Syndromes; Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
Vopikitug RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Solid tumours; Neoplasms Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases; Psoriasis; Dermatitis, Atopic Details
IL2 CD25 fusion protein (Bristol-Myers Squibb) Phase 1 Clinical University Of Miami Autoimmune Diseases Details
9MW-3911 9MW3911; 9MW-3911 Phase 1 Clinical Nanjing Nuo Aixin Biotechnology Co Ltd Neoplasms Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
BMS-986326 BMS-986326 Phase 1 Clinical Bristol-Myers Squibb Company Lupus Vulgaris; Dermatitis, Atopic Details
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) Institute Of Hematology & Blood Diseases Hospital Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Plc Graft vs Host Disease Details
Nemvaleukin alfa RDB-1419; RDB-1450; ALKS-4230 Phase 3 Clinical Alkermes Plc Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
PT-101 PT-101; MK-6194; PT101 Phase 2 Clinical Pandion Therapeutics Lupus Erythematosus, Systemic; Colitis, Ulcerative; Dermatitis, Atopic; Vitiligo Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Melanoma Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Adc Therapeutics Sa, Genmab A/S Myeloproliferative Disorders; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myelodysplastic Syndromes; Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic Details
Vopikitug RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
BA-1106 TS-1904; BA-1106; RR-102 Phase 1 Clinical Solid tumours; Neoplasms Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Inc Autoimmune Diseases; Psoriasis; Dermatitis, Atopic Details
IL2 CD25 fusion protein (Bristol-Myers Squibb) Phase 1 Clinical University Of Miami Autoimmune Diseases Details
9MW-3911 9MW3911; 9MW-3911 Phase 1 Clinical Nanjing Nuo Aixin Biotechnology Co Ltd Neoplasms Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
BMS-986326 BMS-986326 Phase 1 Clinical Bristol-Myers Squibb Company Lupus Vulgaris; Dermatitis, Atopic Details
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) Institute Of Hematology & Blood Diseases Hospital Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap